Dementia and Alzheimer Disease

Findings show that apathy affects more than half of individuals with LBD, challenging assumptions that it emerges only in later stages and underscoring the need for targeted screening tools and intervention strategies.

The head of medical development for donanemab at Eli Lilly and Company explained how donanemab’s modified titration dosing regimen could reduce ARIA risk and improve clinical decision-making following the drug’s FDA label update. [WATCH TIME: 3 minutes]

The head of medical development for donanemab at Eli Lilly and Company provided insights on the structure of TRAILBLAZER-ALZ 6, a study comparing numerous different dosing regimens of donanemab. [WATCH TIME: 3 minutes]

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is on progressive multiple sclerosis.

Elisabeth Marsh, MD, an associate professor of neurology at Johns Hopkins, shared her insights on the emerging role of AI in clinical practice and neurologic education, ahead of her session at the 2025 ANA/AUPN Annual Meetings.

Andrew Varga, MD, PhD, associate professor of medicine at the Icahn School of Medicine at Mount Sinai, provided comment on a featured debate at the 2025 SLEEP Annual Meeting exploring the evolving science behind glymphatic clearance and its potential link to Alzheimer disease.

Nuri Jacoby, MD, neurologist at Maimonides Medical Center and SUNY Downstate, previewed a hands-on session at the upcoming AUP Annual Meeting exploring how simulations can teach communication, professionalism, and feedback skills in neurology training.

A recent study highlighted key unmet needs and barriers that may lead to preventable nursing home placements among Black, Hispanic/Latino, and White patients living with dementia.

INmune Bio's XPro shows promise as a treatment for patients with Alzheimer disease, revealing cognitive benefits despite mixed phase 2 trial results.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is on the Alzheimer's Association International Conference.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending July 11, 2025.

A recent study confirmed ambroxol's safety in Parkinson disease dementia, showing stabilization of neuropsychiatric symptoms but no cognitive improvement.

The updated donanemab dosing schedule is aimed at reducing ARIA risk while maintaining efficacy in early Alzheimer treatment to enhance patient safety.

The professor of neurology at the Miami Miller School of Medicine discussed how the Cognivue Amyloid Risk Measure (CARM) may help predict amyloid presence and informs diagnosis, trial eligibility, and early treatment pathways.

Catch up on any of the neurology news headlines you may have missed over the course of June 2025, compiled all into one place by the NeurologyLive® team.

As the first FDA-approved treatment for Alzheimer agitation, brexpiprazole showcased effective symptom relief with a favorable safety profile.

Overviewing the major clinical trial readouts in neurology from the first half of 2025, with data that could reshape patient care.

The FDA expands Vizamyl's use for Alzheimer diagnosis and therapy monitoring, enhancing patient care with precise amyloid quantification.

Omonigho Michael Bubu, MD, PhD, an associate professor of psychiatry, neurology, & population health at NYU Langone, discussed how OSA contributes to Alzheimer disease risk through race- and sex-specific mechanisms and neurodegenerative biomarkers.

Researchers uncover a latent infection model for Creutzfeldt-Jakob disease, revealing insights into its mysterious origins and potential triggers.

The neuroscientist and physician at Mount Sinai explored the role of sleep-dependent brain clearance in Alzheimer disease and how emerging research is challenging longstanding assumptions.

Prespecified analyses showed that obicetrapib significantly reduced primary outcome measure of Alzheimer disease biomarkers in both the overall population and APOE4 carriers.

Catch up on any of the neurology news headlines you may have missed over the course of May 2025, compiled all into one place by the NeurologyLive® team.

Neurology News Network. for the week ending May 31, 2025. [WATCH TIME: 4 minutes]

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending May 30, 2025.